Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Net Income: 2015-2025

Historic Net Income for Editas Medicine (EDIT) over the last 11 years, with Sep 2025 value amounting to -$25.1 million.

  • Editas Medicine's Net Income rose 59.58% to -$25.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$197.6 million, marking a year-over-year increase of 6.13%. This contributed to the annual value of -$237.1 million for FY2024, which is 56.38% down from last year.
  • As of Q3 2025, Editas Medicine's Net Income stood at -$25.1 million, which was up 51.21% from -$51.5 million recorded in Q2 2025.
  • Editas Medicine's 5-year Net Income high stood at -$18.9 million for Q4 2023, and its period low was -$75.7 million during Q1 2025.
  • In the last 3 years, Editas Medicine's Net Income had a median value of -$47.5 million in 2023 and averaged -$49.2 million.
  • In the last 5 years, Editas Medicine's Net Income slumped by 524.32% in 2021 and then soared by 68.95% in 2023.
  • Over the past 5 years, Editas Medicine's Net Income (Quarterly) stood at -$41.4 million in 2021, then tumbled by 46.58% to -$60.7 million in 2022, then surged by 68.95% to -$18.9 million in 2023, then slumped by 140.68% to -$45.4 million in 2024, then skyrocketed by 59.58% to -$25.1 million in 2025.
  • Its Net Income stands at -$25.1 million for Q3 2025, versus -$51.5 million for Q2 2025 and -$75.7 million for Q1 2025.